Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Observační studie, která se dozví více o bezpečnosti darolutamidu u mužů s rakovinou prostaty v Koreji

4. listopadu 2026 aktualizováno: Bayer

Postmarketingová sledovací studie pro schválené použití darolutamidu u korejských pacientů

This is an observational study in which participants receive a treatment which is already available for doctors to prescribe for non-metastatic castration-resistant prostate cancer (nmCRPC) or metastatic hormone-sensitive prostate cancer (mHSPC). nmCRPC is a prostate cancer that has not yet spread to other parts of the body and does not respond to lowering testosterone in the body. mHSPC is a prostate cancer that has spread to other parts of the body and can be treated by lowering testosterone levels.

This study looks at the safety of the study drug, darolutamide, in Korean patients with nmCRPC or mHSPC. Darolutamide is currently available for doctors to prescribe to men with nmCRPC or mHSPC. It works by attaching to the special molecules called androgen receptors (AR) within prostate cells and blocks hormones called androgens from attaching to AR, which helps delay cancer growth.

To learn more about the safety of Darolutamide, the researchers will study whether the participants have adverse events. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments. The researchers will also learn more about how well darolutamide is working in these participants.

During this study, the researchers will collect information from the medical records of patients who have been prescribed darolutamide by their doctors.

Each participant will be in this study for 1 year. The whole study will last about 6 years. During this time, the participants will visit their doctor every 2 to 4 months as part of their usual care. At these visits, the doctors will do scans to check the patients' cancer and take blood samples. The patients will answer questions about any medications they are taking and whether they have any adverse events.

Přehled studie

Postavení

Nábor

Podmínky

Intervence / Léčba

Typ studie

Pozorovací

Zápis (Odhadovaný)

600

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

      • Many Locations, Jižní Korea
        • Nábor
        • Many locations

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

19 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Mužský

Metoda odběru vzorků

Vzorek nepravděpodobnosti

Studijní populace

Patients who have been prescribed Darolutamide for a medically appropriate use will be eligible to be enrolled.

Popis

Inclusion Criteria:

  • Male aged ≥19 years

  • Patients with high risk nmCPRC

    • Castrate level of serum testosterone (< 1.7 nmol/l [50 ng/dL])
    • PSA doubling time < 10 months
  • Patients with mHSPC

    • histologically or cytologically confirmed prostate cancer, and metastases detected on bone scanning, contrast-enhanced computed tomography (CT), or magnetic resonance imaging (MRI).
    • be candidates for androgen-deprivation therapy with/without docetaxel.
  • Patients for whom the decision to initiate treatment with Darolutamide as a first time was made as per investigator's routine treatment practice

  • Written informed consent from subject or legal representative; assent from subject when appropriate

Exclusion Criteria:

  • Patients participating in an investigational program with interventions outside of routine clinical practice
  • Participants with contraindication according to the locally approved prescribing information

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Observační modely: COHORT
  • Časové perspektivy: PROSPECTIVE

Kohorty a intervence

Skupina / kohorta
Intervence / Léčba
Male patients with nmCRPC or mHSPC

Male patients with a diagnosis of non-metastatic castration-resistant prostate cancer (nmCRPC) or metastatic hormone-sensitive prostate cancer (mHSPC) will be enrolled after the decision for treatment with Darolutamide has been made by the investigator.

The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Number, severity of adverse events (including SAEs)
Časové okno: From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)

SAE stands for serious adverse event. An adverse event (AE) is any untoward medical occurrence in a patient administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
Number, severity of adverse drug reactions (including SADRs)
Časové okno: From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)

SADR stands for serious adverse drug reaction. An ADR is any AE judged by investigator as having a reasonable suspected causal relationship to Darolutamide.

From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
The outcome of (serious) adverse events
Časové okno: From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)

An adverse event (AE) is any untoward medical occurrence in a patient administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
The outcome of (serious) adverse drug reactions
Časové okno: From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)

An ADR is any AE judged by investigator as having a reasonable suspected causal relationship to Darolutamide.

From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Důvody ukončení Darolutamidu
Časové okno: Až 52 týdnů
Až 52 týdnů
Dávkování a úprava dávky darolutamidu
Časové okno: Až 52 týdnů
Až 52 týdnů
Metastasis-free survival (MFS) by nmCRPC indication
Časové okno: Up to 52 weeks

MFS is defined as the time (months) from the initiation of Darolutamide treatment to the date of first observed metastasis.

Up to 52 weeks
Time to first symptomatic skeletal event (SSE) by nmCRPC indication
Časové okno: Up to 52 weeks

Time to SSE is defined as the time (months) from the initiation of Darolutamide treatment to the date of first diagnosed skeletal-related event.

Up to 52 weeks
Time to prostate-specific antigen (PSA) progression by nmCRPC indication
Časové okno: Up to 52 weeks

Time to PSA progression is defined as the time (months) from the initiation of Darolutamide treatment to the date at which PSA is recorded at ≥25% increase above the nadir (lowest screening or baseline) value along with an increase in absolute value of ≥2 ng/mL above nadir.

Up to 52 weeks
Overall survival by nmCRPC indication
Časové okno: Up to 52 weeks

Overall survival is defined as the time (months) from the initiation of Darolutamide treatment until death from any cause.

Up to 52 weeks
Time to Castration-Resistant Prostate Cancer (CRPC) by mHSPC indication
Časové okno: Up to 52 weeks

Time to mCRPC, defined as the time to PSA progression with serum testosterone being at castrate level <0.50 ng/mL, or the time to progression by soft tissue/visceral lesions or time to progression by bone lesions, whatever comes first.

Up to 52 weeks
Time to first symptomatic skeletal event (SSE) by mHSPC indication
Časové okno: Up to 52 weeks

Time to SSE is defined as the time (months) from the initiation of Darolutamide treatment to the date of first diagnosed skeletal-related event.

Up to 52 weeks
Time to prostate-specific antigen (PSA) progression by mHSPC indication
Časové okno: Up to 52 weeks

Time to PSA progression is defined as the time (months) from the initiation of Darolutamide treatment to the date at which PSA is recorded at ≥25% increase above the nadir (lowest screening or baseline) value along with an increase in absolute value of ≥2 ng/mL above nadir.

Up to 52 weeks
Overall survival by mHSPC indication
Časové okno: Up to 52 weeks

Overall survival is defined as the time (months) from the initiation of Darolutamide treatment until death from any cause.

Up to 52 weeks
Time to initiation of subsequent anti-cancer therapy by mHSPC indication
Časové okno: Up to 52 weeks

Time to initiation of subsequent anti-cancer therapy is defined as the time (months) from the initiation of Darolutamide treatment to the date of first administration of any subsequent anti-cancer therapy after discontinuation of Darolutamide.

Up to 52 weeks
Radiological progression (Soft tissue/ Bone metastasis) by mHSPC indication
Časové okno: Up to 52 weeks

Radiological progression is defined as the time (months) from the start of Darolutamide treatment to the date of first documentation of radiological progressive disease or death due to any cause, whichever occurs first.

Up to 52 weeks
Radiological Progression-Free Survival (rPFS) by mHSPC indication
Časové okno: Up to 52 weeks

Radiographic Progression-Free Survival (rPFS) is defined as the time (months) from the initiation of Darolutamide treatment to the date of the first radiologically confirmed disease progression or death from any cause, whichever occurs first.

Up to 52 weeks
Duration of Darolutamide treatment
Časové okno: Up to 52 weeks

Duration of Darolutamide treatment is defined as the time (months) from the start of Darolutamide treatment to the day of permanent discontinuation of Darolutamide (including death).

Up to 52 weeks

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

25. září 2024

Primární dokončení (Odhadovaný)

31. března 2028

Dokončení studie (Odhadovaný)

30. června 2028

Termíny zápisu do studia

První předloženo

21. března 2024

První předloženo, které splnilo kritéria kontroly kvality

21. března 2024

První zveřejněno (Aktuální)

27. března 2024

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

5. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

4. listopadu 2026

Naposledy ověřeno

4. listopadu 2026

Více informací

Termíny související s touto studií

Další relevantní podmínky MeSH

Další identifikační čísla studie

  • 20654

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Popis plánu IPD

Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.

Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .